Aug 25, 2026 07:02AM
Aug 25, 2026 07:01AM
Aug 5, 2026 07:00AM
Jun 29, 2026 07:00AM
Jun 29, 2026 07:00AM
Jun 12, 2026 07:00AM
Jun 12, 2026 07:00AM BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
May 27, 2026 07:00AM
May 6, 2026 07:00AM
May 4, 2026 07:01AM
May 4, 2026 07:00AM
Apr 6, 2026 07:00AM
Apr 6, 2026 07:00AM
Feb 26, 2026 07:00AM BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
Feb 11, 2026 07:00AM
Jan 23, 2026 09:00AM
Jan 23, 2026 09:00AM
Jan 12, 2026 07:04AM
Jan 12, 2026 07:00AM
Dec 12, 2025 07:00AM
Dec 12, 2025 07:00AM BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
Nov 16, 2025 03:00PM
Nov 12, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 3, 2025 07:00AM
Oct 23, 2025 07:00AM
Oct 14, 2025 07:00AM BioCryst to acquire Astria Therapeutics for $920 million
Oct 14, 2025 07:00AM
Sep 11, 2025 08:18AM
Aug 11, 2025 07:02AM
Aug 11, 2025 07:00AM
Aug 4, 2025 07:00AM
Jul 31, 2025 07:00AM
Jul 31, 2025 07:00AM BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
Jul 9, 2025 07:00AM
Jul 7, 2025 07:01AM
Jul 7, 2025 07:00AM
Jun 16, 2025 07:02AM
Jun 16, 2025 07:00AM
Jun 13, 2025 07:00AM
Jun 13, 2025 07:00AM ORLADEYO® (berotralstat) Approved in Colombia
Jun 6, 2025 07:00AM
Jun 6, 2025 07:00AM
Jun 2, 2025 07:00AM
May 30, 2025 07:01AM
May 30, 2025 07:00AM
May 16, 2025 07:01AM
May 16, 2025 07:00AM BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
May 14, 2025 07:00AM

330,183 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All